Regenxbio shares new mid-stage data for its wet AMD gene therapy
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
Nurix Therapeutics’ BTK degrader has elicited responses in a small group of patients with certain cancers, supporting the biotech’s claim that the drug could potentially
Plus, news about Takeda, Foresee Pharmaceuticals and Capricor Therapeutics: GSK, Cambridge University team up on immune diseases: The UK drugmaker is pouring £50 million …
Some, though certainly not all, chief indicators of biotech business activity are pointed shakily north as we head into a critical Q4. But biotech shows
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
The team at Seaport Therapeutics, a Boston neuropsychiatry biotech, is having a good fall season. Seaport said Monday it has pieced together $225 million from
Hearing loss was linked with higher Parkinson’s disease risk. Severity of hearing loss was tied to incident Parkinson’s in a dose-dependent way. Early interventions with
A shorter regimen of three cycles of adjuvant chemotherapy was noninferior to a standard six-cycle regimen among patients with pathologically high-risk retinoblastoma, a Chinese randomized